Table 2.
Class of Antimicrobial | Name | Source | Cellular Target | MIC | Ref. |
---|---|---|---|---|---|
Small Molecule | VUF 15259 | Autotransporter (AT) pathway | N/A | Steenhuis et al., 2019. [51] | |
Nitazoxanide (NTZ) | BamB, BamE, BamD | N/A | Psonis et al., 2019. [68] | ||
MRL-494 | BamA (Gram-negatives); Cytoplasmic membrane integrity (Gram-positives) | 25 μM (E. coli JCM320) | Hart et al., 2019. [39] | ||
IMB-H4 | BamA, BamD | 4 μg/mL (E. coli ATCC 25922) | Li et al., 2020. [69] | ||
Peptide/Protein | |||||
Antibodies | MAB1 (monoclonal antibody) |
Mouse/rat | BamA | N/A | Storek et al., 2018. [46] |
anti-BamA monoclonal antibodies | Rat | BamA | N/A | Vij et al., 2018. [70] | |
Fabs/Nanobodies | Fab1 | BamA | N/A | White et al., 2021. [71] | |
nanoE6 | BamA | N/A | Kaur et al., 2019. [72] | ||
nanoE7 | BamA | N/A | Kaur et al., 2019. [72] | ||
Peptides | JB-95 (β-hairpin peptidomimetic) | possibly BamA or LptD; active against Gram-positives | 0.15 μg/mL E. coli (E. coli ATCC 25922) | Urfer et al., 2016. [73] | |
FIRL (BamD mimic) |
BamD | No solo antimicrobial activity; synergizes with existing drugs to lower MIC | Mori et al., 2012. [74] | ||
Chimeric peptidomimetic antibiotics (peptides 3, 4, 7, 8) | BamA, LPS | Luther et al., 2019. [45] | |||
Peptide 2 (BamA mimic) |
E. coli | BamD | N/A | Hagan et al., 2015. [75] | |
Antibacterial peptide | Axinella donnani | BamA | N/A | Vimala et al., 2015. [76] | |
Darobactin A | Photorhabdus khanii | BamA | 4 μg/mL (E. coli MG1655) 2 μg/mL (E. coli ATCC 25922) |
Imai et al., 2019. [40] | |
Dynobactin A | Photorhabdus australis | BamA | 16 μg/mL (E. coli MG1655) 8 μg/mL (E. coli ATCC 25922) |
Miller et al., 2022. [48] | |
Lectin-like bacteriocins | LlpA | BamA | N/A | Ghequire et al., 2018; Ghequire et al., 2019. [38,77] |